Skip to main content
Acta Crystallographica Section F: Structural Biology Communications logoLink to Acta Crystallographica Section F: Structural Biology Communications
. 2014 Mar 25;70(Pt 4):505–508. doi: 10.1107/S2053230X14005081

Expression, crystallization and preliminary X-ray crystallographic analysis of d-alanine-d-alanine ligase from OXA-23-producing Acinetobacter baumannii K0420859

Kim-Hung Huynh a,, Huyen-Thi Tran b,, Tan-Viet Pham b, Ho-Phuong-Thuy Ngo a, Sun-Shin Cha c, Kyung Min Chung d, Sang Hee Lee e, Lin-Woo Kang a,*
PMCID: PMC3976074  PMID: 24699750

OXA-23-producing A. baumannii K0420859 can resist the action of carbapenem, and causes bacteraemia, pneumonia, other respiratory-tract and urinary-tract infections in humans. As a novel target for an antibacterial drug against A. baumannii OXA-23, d-alanine-d-alanine ligase from A. baumannii was purified and crystallized, and a primary X-ray crystallographic analysis was performed.

Keywords: OXA-23-producing Acinetobacter baumannii, cell-wall synthesis, d-alanine-d-alanine ligase

Abstract

Acinetobacter baumannii causes bacteraemia, pneumonia, other respiratory-tract and urinary-tract infections in humans. OXA-23 carbapenemase-producing A. baumannii K0420859 (A. baumannii OXA-23) is resistant to carbapenem, a common antibacterial drug. To develop an efficient and novel antibacterial drug against A. baumannii OXA-23, d-alanine-d-alanine ligase, which is essential in bacterial cell-wall synthesis, is of interest. Here, the d-alanine-d-alanine ligase (AbDdl) gene from A. baumannii OXA-23 was cloned and expressed, and the AbDdl protein was purified and crystallized; this enzyme can be used as a novel target for an antibacterial drug against A. baumannii OXA-23. The AbDdl crystal diffracted to a resolution of 2.8 Å and belonged to the orthorhombic space group P212121, with unit-cell parameters a = 113.4, b = 116.7, c = 176.5 Å, a corresponding V M of 2.8 Å3 Da−1 and a solvent content of 56.3%, and six protomers in the asymmetric unit.

1. Introduction  

Acinetobacter baumannii is a Gram-negative short, round or rod-shaped bacterium. A. baumannii causes bacteraemia, pneumonia, other respiratory-tract and urinary-tract infections in humans, and has become an important causative agent of nosocomial infections. The ability of A. baumannii to improve its resistance mechanisms and survival time makes it difficult to eradicate A. baumannii infections from the clinical system (Liakopoulos et al., 2012; Espinal et al., 2013). Carbapenems have been widely used to treat A. baumannii infections, but a worldwide trend of increasing resistance to these antibiotics associated with the production of acquired carbapenem-hydrolyzing OXA-type class D β-lactamases has been reported. Until recently, A. baumannii strains resistant to carbapenem have been identified and grouped into four main groups according to the β-lactamase produced by them: OXA-23, OXA-24, OXA-51 and OXA-58 (Lee et al., 2011).

We analyzed OXA-23-producing A. baumannii K0420859 (A. baumannii OXA-23) strain carrying the bla OXA-23 gene primarily located on plasmids or intergrons (Bogaerts et al., 2008). The A. baumannii OXA-23 strain was first identified in Spain in 2010 (Espinal et al., 2013). In the case of other carbapenem-resistant A. baumannii strains, no drugs that can completely inhibit A. baumannii OXA-23 have been found. d-Alanine-d-alanine ligase catalyzes the formation of the precursor of peptidoglycan, an essential component of the bacterial cell wall, which has been a novel target for antibacterial drug development (Doan et al., 2008). Recently, several antibiotics directed at inhibiting bacterial cell-wall synthesis have been developed.

Here, we report the cloning of the d-alanine-d-alanine ligase (AbDdl) gene of A. baumannii OXA-23, the expression, purification and crystallization of AbDdl and the preliminary X-ray crystallographic analysis of its crystals. The atomic resolution structure of AbDdl will be helpful in developing a novel antibacterial drug against A. baumannii OXA-23.

2. Methods  

2.1. Cloning  

The gene encoding the Ddl (AbDdl) protein from A. baumannii OXA-23 was cloned by polymerase chain reaction (PCR). The sequences of the oligonucleotide primers were designed based on the data on the genome sequences of other A. baumannii strains from the NCBI website. The forward and reverse primers 5′-CCC CCC ATA TGT CAA ATG CTA CAA AAT TCG GC-3′ and 5′-CCC CCG GAT CCT TAA GCC GTA CCT TCC AAT GT-3′, respectively, contain NdeI and BamHI restriction sites denoted by the bold letters. After double-digestion with NdeI and BamHI enzymes, the PCR product was inserted into a modified pET11a vector; the pET11a vector (Novagen) was engineered to have additional residues of a 7×His tag and a Tobacco etch virus (TEV) protease-cleavage site before the NdeI site.

2.2. Overexpression and purification  

The recombinant vector pET11a-AbDdl was transformed into Escherichia coli strain BL21 (DE3) pLysS and the E. coli cells were cultured in Luria–Bertani medium containing 50 µg ml−1 ampicillin. Overexpression of AbDdl was induced by adding 0.5 mM isopropyl β-d-1-thiogalactopyranoside (IPTG) to the culture at 310 K until an OD600 of 0.6 was observed. After induction, the cells were cultured for an additional 4 h. The cultured cells were harvested by centrifugation for 20 min at 6000g (Supra 30K A1000S-4 rotors, Hanil, Seoul, Republic of Korea) at 277 K. The cell pellets were then resuspended in ice-cold lysis buffer (25 mM Tris–HCl pH 7.5, 300 mM NaCl, 15 mM imidazole, 3 mM β-mercaptoethanol) and homogenized by ultrasonication on ice (Sonomasher, S & T Science, Republic of Korea). The lysate was then centrifuged for 40 min at 21 000g (Vision VS24-SMTi V508A rotor) at 277 K. About 40% of the total expressed AbDdl was observed to be soluble (data not shown). The supernatant containing soluble AbDdl was loaded onto an Ni2+-charged resin (Ni-NTA His·Bind Resin, Bio-Rad) previously equilibrated with the lysis buffer. Affinity purification was performed according to the manufacturer’s protocol at 277 K. The lysis buffer was used to wash out the nonspecifically bound proteins. AbDdl was eluted using an elution buffer consisting of 25 mM Tris–HCl pH 7.5, 300 mM NaCl, 250 mM imidazole, 3 mM β-mercaptoethanol. The resulting protein solution was dialyzed for 12 h at 277 K in buffer A (25 mM Tris–HCl pH 7.5, 3 mM β-mercaptoethanol). The His tag was cleaved using TEV protease at 277 K at a ratio of 20:1 (AbDdl:TEV) by weight in an overnight reaction. Almost 80% of the total AbDdl was cleaved and was then purified again using Ni2+-charged resin. After that, the AbDdl without the His tag was further purified by anion-exchange chromatography using a Hi-Trap Q FF column (GE Healthcare) (Fig. 1). The protein was then concentrated to 11 mg ml−1 in crystallization buffer (25 mM Tris–HCl pH 7.5, 5 mM NaCl, 3 mM β-mercaptoethanol) by using Vivaspin 20 (10000 MWCO, Satorius).

Figure 1.

Figure 1

Purified AbDdl on 12% SDS–PAGE. Lane M contains molecular-mass marker.

2.3. Crystallization and X-ray diffraction data collection  

The crystallization trials were initially conducted at 287 K by the sitting-drop vapour-diffusion method in a 96-well Intelli-Plate (Art Robbins) using a Hydra II e-drop automated pipetting system (Matrix) and the Crystal Screen Lite, Crystal Screen Cryo, PEGRx (Hampton Research), Wizard Precipitant Synergy (Emerald Bio) and Morpheus (Molecular Dimensions) screening kits. We developed several different crystallization conditions, and a condition consisting of 0.06 M MgCl2, CaCl2, 0.1 M imidazole, MES–HCl at pH 6.5 and 30% of precipitant EDO-P8K containing 40%(v/v) ethylene glycol and 20%(w/v) polyethylene glycol 8000 was chosen as the best for crystal growth, while maintaining the protein concentration at 10 mg ml−1. Crystals grew in the abovementioned condition after 2 d (Fig. 2). The fully grown crystals were flash-cooled in liquid nitrogen using a cryoprotectant consisting of the reservoir solution plus 20%(v/v) glycerol. X-ray diffraction data for the crystals were collected using an ADSC Quantum 270 CCD detector on beamline 7A at the Pohang Accelerator Laboratory, Pohang University of Science and Technology, Republic of Korea. The statistics of the data collection are summarized in Table 1.

Figure 2.

Figure 2

A single AbDdl crystal.

Table 1. Data-collection statistics.

Values in parentheses are for the outer shell.

Source Beamline 7A, PAL
Wavelength (Å) 0.97935
Detector ADSC Q270 CCD
Temperature of data collection (K) 100
Crystal-to-detector distance (mm) 350
Rotation range per image (°) 1
Total rotation range (°) 360
Exposure time per image (s) 5
Resolution range (Å) 50.0–2.8 (2.85–2.80)
Space group P212121
Unit-cell parameters (Å) a = 113.4, b = 116.7, c = 176.5
Total No. of reflections 413163
No. of unique reflections 55982
Completeness (%) 96 (92)
Molecules per asymmetric unit 6
V M3 Da−1) 2.8
Solvent content (%) 56.3
Average 〈I/σ(I)〉 12.9 (1.6)
R merge (%) 9.1 (42.0)
Multiplicity 7.4 (3.7)

R merge = Inline graphic Inline graphic, where I(hkl) is the intensity of reflection hkl, Inline graphic is the sum of the overall reflections and Inline graphic is the sum over the i measurements of reflection hkl.

3. Results  

AbDdl was successfully overexpressed and purified by affinity chromatography and anion-exchange chromatography. The homogeneity of the purified protein was examined by SDS–PAGE (Fig. 1). Only one band was visible on SDS–PAGE after a two-step purification, indicating that the purified protein has a molecular weight of about 35 kDa, which is in agreement with the predicted molecular weight of 34.4 kDa. X-ray diffraction data were collected to a resolution of 2.8 Å. The crystallographic orthorhombic space group P212121 with unit-cell parameters a = 113.4, b = 116.7, c = 176.5 Å was determined by auto-indexing (Otwinowski & Minor, 1997). According to the Matthews coefficient calculation, there are six molecules in the asymmetric unit with a solvent content of 56.3% (Matthews, 1968). Analysis of the self-rotation peaks revealed the presence of three twofold, two threefold and one fourfold rotation axes, in addition to three crystallographic twofold axes (Fig. 3). The crystal structure was determined via molecular replacement (MR) using AutoMR from the PHENIX package of crystallographic programs (Adams et al., 2010; McCoy et al., 2007). The search model was generated using CHAINSAW in the CCP4 package (Stein, 2008; Winn et al., 2011) and d-alanine-d-alanine ligase from Yersinia pestis (PDB entry 3v4z; 53% sequence identity; Center for Structural Genomics of Infectious Diseases, unpublished work). The MR was successful and indicated the presence of six protomers in the asymmetric unit. The MR solution model was inputted into AutoBuild (Terwilliger, 2002, 2004; Terwilliger et al., 2008; Zwart et al., 2005; Afonine et al., 2012; Adams et al., 2010) from the PHENIX package. The noncrystallographic rotation axes were confirmed with the MR solution model (Table 2). The current model, with an R factor of 26.0% and an R free of 30.0%, showed good crystal packing. The AbDdl structure thus determined will be useful in developing an antibacterial drug against A. baumannii.

Figure 3.

Figure 3

Self-rotation function of the AbDdl crystal.

Table 2. Noncrystallographic rotation axes between the protomers in the asymmetric unit.

The protein chain IDs of six protomers of AbDdl are depicted as A, B, C, D, E and F.

  A B C D E F
A   Twofold Threefold Twofold Threefold Twofold
B     Twofold Fourfold Twofold Threefold
C       Twofold Fourfold Twofold
D         Twofold Threefold
E           Threefold
F            

Acknowledgments

We are grateful to the staff members at beamline 7A of the Pohang Accelerator Laboratory, Pohang University of Science and Technology, Republic of Korea. This work was supported by the Next-Generation BioGreen 21 Program (PJ009500), Rural Development Administration, Republic of Korea, by the National Research Foundation of Korea grant No. NRF-2012R1A2A2A02005978 and by the National Research Laboratory Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (No. 2011-0027928).

References

  1. Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221.
  2. Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367. [DOI] [PMC free article] [PubMed]
  3. Bogaerts, P., Cuzon, G., Naas, T., Bauraing, C., Deplano, A., Lissoir, B., Nordmann, P. & Glupczynski, Y. (2008). Antimicrob. Agents Chemother. 52, 4205–4206. [DOI] [PMC free article] [PubMed]
  4. Doan, T. T. N., Kim, J.-K., Kim, H., Ahn, Y.-J., Kim, J.-G., Lee, B.-M. & Kang, L.-W. (2008). Acta Cryst. F64, 1115–1117. [DOI] [PMC free article] [PubMed]
  5. Espinal, P., Macià, M. D., Roca, I., Gato, E., Ruíz, E., Fernández-Cuenca, F., Oliver, A., Rodríguez-Baño, J., Bou, G., Tomás, M. & Vila, J. (2013). Antimicrob. Agents Chemother. 57, 589–591. [DOI] [PMC free article] [PubMed]
  6. Lee, J. H., Sohn, S. G., Jung, H. I., An, Y. J., Lee, J. J., Kang, L.-W. & Lee, S. H. (2011). Indian J. Biochem. Biophys. 48, 395–398. [PubMed]
  7. Liakopoulos, A., Miriagou, V., Katsifas, E. A., Karagouni, A. D., Daikos, G. L., Tzouvelekis, L. S. & Petinaki, E. (2012). Euro Surveill. 17, article 2. [PubMed]
  8. Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
  9. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674. [DOI] [PMC free article] [PubMed]
  10. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 277, 307–326. [DOI] [PubMed]
  11. Stein, N. (2008). J. Appl. Cryst. 41, 641–643.
  12. Terwilliger, T. C. (2002). Acta Cryst. D58, 2213–2215. [DOI] [PMC free article] [PubMed]
  13. Terwilliger, T. (2004). J. Synchrotron Rad. 11, 49–52. [DOI] [PubMed]
  14. Terwilliger, T. C., Grosse-Kunstleve, R. W., Afonine, P. V., Moriarty, N. W., Zwart, P. H., Hung, L.-W., Read, R. J. & Adams, P. D. (2008). Acta Cryst. D64, 61–69. [DOI] [PMC free article] [PubMed]
  15. Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
  16. Zwart, P. H., Grosse-Kunstleve, R. W. & Adams, P. D. (2005). CCP4 Newsl. Protein Crystallogr. 43, contribution 7.

Articles from Acta Crystallographica. Section F, Structural Biology Communications are provided here courtesy of International Union of Crystallography

RESOURCES